Evidence map›Paper›PMID 36254212›Full record

ArticleArthroplasty today2022

Recurrent Failures After 2-Stage Exchanges are Secondary to New Organisms Not Previously Covered by Antibiotics.

Fortune J Egbulefu, JaeWon Yang, John C Segreti, Scott M Sporer, Antonia F Chen, Matthew S Austin, Craig J Della Valle

Open access · goldAbstract read
In one paragraph

Article in Arthroplasty today, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Fortune J EgbulefuDepartment of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA.
JaeWon YangDepartment of Orthopaedic Surgery, University of Washington, Seattle, WA, USA.
John C SegretiDepartment of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA.
Scott M SporerDepartment of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA.
Antonia F ChenDepartment of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Matthew S AustinDepartment of Orthopaedic Surgery, Rothman Orthopaedic Institute, Philadelphia, PA, USA.
Craig J Della ValleDepartment of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA.
Rush University Medical Center · USBrigham and Women's Hospital · USRothman Orthopaedics · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prior studies have shown that the majority of re-infections following two-stage revisions are due to organisms different from the initial organisms identified. It remains unknown whether these new organisms were susceptible to the antibiotics given (indicating the patient likely developed another infection following successful treatment) or not susceptible (indicating these organisms may have been initially present, but were not identified, and thus, inadequately treated). The purpose of this study was to determine if bacteria identified at time of re-infection following two-stage revisions were susceptible to the antibiotics administered during treatment of the index infection, in order to understand if these are new infections or from organisms that were present but not initially identified. Methods: Thirty failures (19 knees and 11 hips) following two-stage revisions from four institutions were identified. Cultures and antibiotic sensitivities were used to determine whether the re-infectious organisms were new and if they were susceptible to the antibiotics initially given. Results: Twenty-five (83.3%) re-infections were due to new organisms. Of these re-infections from new organisms, 16 (64.0%) were susceptible to the antibiotics previously administered, suggesting they were new infections rather than persistent infections from organisms that were not detected during initial treatment. No statistically significant differences in demographics or time to revision were observed when comparing by organism type (new vs. repeat) or by antibiotic susceptibility. Conclusions: Failures following two-stage revisions are frequently due to organisms different than those identified prior to two-stage revision and are likely new infections rather than persistent infections from undetected organisms.

Indexed as

Antibiotic sensitivitiesAntibiotic susceptibilityPeriprosthetic joint infectionRecurrent infectionTwo-stage exchange

Identifiers

PMID36254212
PMCPMC9568676
OpenAlexW4293321641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.